Skip to main content

Table 2 Baseline characteristics for patients in the development and validation cohorts according to non-achievement of remission

From: Validation of prediction models of severe disease course and non-achievement of remission in juvenile idiopathic arthritis part 2: results of the Nordic model in the Canadian cohort

qNordic development cohort (N = 427)ReACCh-Out validation cohort (N = 506)
Remission (n = 181)Non-remission (n = 246)Remission (n = 98)Non-remission (n = 408)
Characteristics
 Age at onset, years5.9 (2.5, 10.0)*5.2 (2.5, 9.5)8.0 (3.6, 11.5)7.2 (2.6, 11.1)
 Female, n (%)115 (63.5)169 (68.7)62 (63.3)285 (70.4)
 Onset to enrolment, months7 (6, 8)6.5 (6, 8)3.9 (2.4, 6.0)5.1 (2.7, 9.7)
JIA category, n (%)**
 Oligoarthritis107 (59.1)111 (45.1)55 (56.1)137 (33.6)
 RF-neg. polyarthritis25 (13.8)68 (27.6)4 (4.1)113 (27.7)
 RF-pos. polyarthritis1 (0.6)3 (1.2)0 (0.0)17 (4.2)
 Systemic15 (8.3)2 (0.8)13 (13.3)28 (6.9)
 Enthesitis-related11 (6.1)23 (9.3)8 (8.2)50 (12.3)
 Psoriatic3 (1.7)3 (1.2)8 (8.2)20 (4.9)
 Undifferentiated19 (10.5)36 (14.6)10 (10.2)43 (10.5)
Assessments and laboratory tests
Active joints, n (%)
 Cervical arthritis13 (7.2)25 (10.2)0 (0.0)26 (7.0)
 Finger arthritis40 (22.1)94 (38.2)16 (19.3)167 (44.7)
 Ankle arthritis65 (35.9)129 (52.4)17 (20.5)186 (49.7)
 Hip arthritis24 (13.3)38 (15.4)7 (8.4)50 (13.4)
 Active joint count***2 (1, 4)4 (2, 7)1 (1, 2)3 (1, 9)
 Physician global assessment0.8 (0.0, 1.3)2.0 (1.0, 3.8)1.9 (1.0, 3.2)3.8 (2.0, 6.0)
 Parent global assessment0.6 (0.0, 2.0)1.7 (0.5, 3.5)0.7 (0.2, 2.4)2.3 (0.7, 4.9)
 Pain0.4 (0.0, 3.0)2.3 (0.5, 4.2)1.0 (0.2, 3.0)3.9 (1.0, 6.1)
 CHAQ DI0.1 (0.0, 0.6)0.5 (0.0, 1.1)0.1 (0.0, 0.5)0.5 (0.1, 1.1)
 Stiffness > 15 min (%)30 (16.6)90 (36.6)45 (55.6)184 (65.0)
 ESR****11.5 (6, 20)17.5 (10, 31)20 (9, 34)21 (9, 40)
 CRP****0.0 (0, 0)0.0 (0, 15)2.0 (0.2, 10)3.0 (0.3, 17)
 ANA37 (20.4)76 (30.9)49 (50.0)182 (50.7)
 RF5 (2.8)5 (2.0)5 (5.1)23 (6.4)
 HLA B2722 (12.2)60 (24.4)5 (5.1)36 (10.0)
Treatment by first study visit (%)
 NSAIDs152 (84.0)215 (87.4)88 (89.8)390 (95.6)
 Joint injections84 (46.4)152 (61.8)24 (24.5)88 (21.6)
 DMARDs20 (11.0)71 (28.9)9 (9.2)137 (33.6)
 Biologics001 (1)1 (0.2)
  1. *Numbers are median (25th centile, 75th centile) or number of patients (%)
  2. **Patients with systemic JIA were excluded from the Nordic prediction model development study. They are included in the validation cohort and in this table
  3. ***The Nordic development cohort used the cumulative active joint count within 6 months of disease onset, and the ReACCh-Out validation cohort used the active joint count at baseline
  4. ****Erythrocyte sedimentation rate measurements were available for 322 of 427 patients (75.4%) in the Nordic cohort and for 458 of 506 patients (90.5%) in the ReACCh-Out cohort. C-reactive protein measurements were available for 345 of 427 patients (80.8%) in the Nordic cohort and 404 of 506 patients (79.8%) in the ReACCh-Out cohort